Vifor Pharma AG
SIX:VIFN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bankruptcy Probability
Vifor Pharma AG's probability of bankruptcy is 1%, making a collapse highly unlikely. The solvency score is 92/100 — a strong indicator of financial stability.
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Vifor Pharma AG Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CH |
V
|
Vifor Pharma AG
SIX:VIFN
|
10.8B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.8B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
213.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Vifor Pharma AG's probability of bankruptcy is 1%, making a collapse highly unlikely.
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Vifor Pharma AG has total debt of 117m CHF. This includes both short-term (0 CHF) and long-term (117m CHF) debt.
You can find a full breakdown on its Balance Sheet.
